United Therapeutics (NASDAQ:UTHR) Surprises With Q2 CY2026 Sales
United Therapeutics: Q2 Earnings Snapshot
United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2026. Total revenues in the second quarter...
Barchart Research What to Expect from UTHR Earnings UTHR Generated August 4, 2026 Current Price $518.68 EPS Estimate $$6.82 Consensus Rating Moderate Buy Average Move 6.67% United Therapeutics Reports...
Earnings To Watch: United Therapeutics (UTHR) Reports Q2 Results Tomorrow
The long-term, pivotal, phase 3 ADVANCE OUTCOMES study of ralinepag in predominantly pre-treated patients with pulmonary arterial hypertension ( PAH ) met its...
United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that the company’s Board of Directors appointed Victor Dzau, M.D. , ...
United Therapeutics Corporation (Nasdaq: UTHR ) announced today that it will report its second quarter 2026 financial results in a press release that will be issued on Wednesday, August...
The flights carried manufactured organs, being developed by United Therapeutics The flights are also the first in a series of use cases that will touch at least 26 states...
United Therapeutics Corporation (Nasdaq: UTHR ) announced today it has acquired Thymmune Therapeutics, Inc. ( Thymmune ), a privately held, preclinical stage biotechnology...